Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. (Vor Bio) (Nasdaq: VOR) is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through the development of telitacicept, a dual BAFF/APRIL fusion protein. The VOR news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Vor Bio’s telitacicept program and corporate strategy evolve over time.
According to recent announcements, Vor Bio’s news flow centers on late-stage clinical data for telitacicept in B‑cell–mediated autoimmune diseases, including generalized myasthenia gravis, Sjögren’s disease, systemic lupus erythematosus, and IgA nephropathy. The company and its collaborator RemeGen Co., Ltd. have reported Phase 3 results from studies conducted in China, including data presented at major medical meetings and in peer‑reviewed publications. These updates highlight efficacy endpoints, durability of response, and safety findings for telitacicept across multiple indications.
Investors following VOR news can also track capital markets activity, such as underwritten public offerings, private placements with institutional healthcare investors, and at‑the‑market equity sales programs disclosed in company press releases and Form 8‑K filings. Additional news items cover leadership and governance changes, including appointments to the Board of Directors and executive team roles like Chief Medical Officer, Chief Development Officer, and Chief Commercial Officer, which Vor Bio links to its late-stage development and potential commercialization plans.
Vor Bio’s participation in healthcare and investor conferences, including events such as the J.P. Morgan Healthcare Conference and other sector-focused meetings, is another recurring news theme. Visitors to this page can review updates on upcoming presentations, webcasts, and corporate slide decks referenced in SEC filings. For anyone monitoring VOR, the news feed offers a centralized view of clinical milestones, financing decisions, and strategic developments related to telitacicept and Vor Bio’s broader autoimmune disease focus.
Vor Bio (Nasdaq: VOR) announced that on October 15, 2025 its Compensation Committee granted inducement awards to 20 newly hired employees under the Vor Biopharma 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards comprise 113,478 stock options and 24,319 RSUs. Options have a 10-year term with an exercise price of $30.22 (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months). RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to the Inducement Plan and individual award agreements.
Vor Bio (Nasdaq: VOR) collaborator RemeGen presented 48-week open-label extension data for telitacicept in generalized myasthenia gravis on Oct 29, 2025.
Key efficacy: continuous-treatment patients had a mean -7.5 MG-ADL change and crossover patients -6.3 at week 48; continuous patients had mean -9.8 QMG change and crossover -9.3. 96.2% of continuous and 90.2% of crossover patients reached ≥3-point MG-ADL improvement; most adverse events were mild‑to‑moderate with no new safety signals.
Vor Bio (Nasdaq: VOR) will host a live webcast to present newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease.
The study was conducted by collaborator RemeGen. Vor Bio management and Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results.
Webcast: Tuesday, October 28, 2025 at 4:30 PM Eastern Time. Registration options include listen-only and listen-with-live Q&A links; a replay will be posted at https://ir.vorbio.com/events-presentations/ approximately two hours after the call and will remain available for 30 days.
Vor Bio (Nasdaq: VOR) said clinical data from Stage A of a China Phase 3 study of telitacicept in adults with IgA nephropathy (IgAN) will be a late-breaking oral presentation at ASN Kidney Week 2025 on Nov 8, 2025 at 10:45 AM CT.
Topline results reported a 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at 39 weeks versus placebo (p<0.0001) and a favorable safety profile. RemeGen has submitted a BLA to China’s CDE/NMPA for IgAN; approval would be telitacicept’s fifth indication in China.
Vor Bio (Nasdaq: VOR) announced publication in The New England Journal of Medicine of a China Phase 3 trial of telitacicept in systemic lupus erythematosus (SLE).
The randomized 335-patient study across 42 hospitals met its primary endpoint at week 52: 67.1% response for telitacicept versus 32.7% for placebo (P<0.001). Key secondary results: SELENA-SLEDAI ≥4 point reduction in 70.1% vs 40.5%; mean SELENA-SLEDAI change -4.95 vs -1.0; median time to flare 198 vs 115 days; steroid reduction in 44.9% vs 34.7%; kidney proteinuria improvements 71.8% vs 55.1%. Safety: more URTI (31.7% vs 19.0%) and injection-site reactions (12.6% vs 0.6%); serious adverse events were lower (7.2% vs 14.3%).
Vor Bio (NASDAQ: VOR) announced positive 48-week China Phase 3 results for telitacicept in primary Sjögren’s disease, presented at ACR Convergence 2025 on October 28, 2025. The 160mg dose met the primary endpoint (change in ESSDAI at week 24) and all secondary endpoints with p<0.0001 versus placebo, showing durable benefit through 48 weeks.
Key metrics: 71.8% of patients on 160mg achieved ≥3-point ESSDAI reduction at week 24 vs 19.3% placebo; mean ESSDAI change at week 24 was -4.4 (160mg) vs -0.6 (placebo). Safety was comparable to placebo with no new signals.
Vor Bio (Nasdaq: VOR) announced on Oct 3, 2025 that on Sept 19, 2025 its Compensation Committee granted inducement awards to eight newly hired employees under the 2023 Inducement Plan.
The grants consist of 76,360 stock options (10‑year term) and 16,361 RSUs. The option exercise price is $30.40 per share (closing price on grant date). Options vest over four years (25% after 12 months, then monthly over 36 months); RSUs vest over four years (25% after 12 months, then quarterly over 36 months). Awards are subject to plan and award agreement terms and continued employment.
Vor Bio (NASDAQ:VOR) announced that clinical data from their Phase 3 study of telitacicept in primary Sjögren's disease will be presented at ACR Convergence 2025 (October 24-29, 2025) in Chicago. The study, conducted in collaboration with RemeGen Co., Ltd, will be featured as a late-breaking poster presentation.
Notably, RemeGen has already submitted a Biologics License Application (BLA) to China's National Medical Products Administration for telitacicept in primary Sjögren's disease. If approved, this will mark telitacicept's fourth approved indication in China.
Vor Bio (Nasdaq: VOR) has appointed Dr. Navid Z. Khan as Chief Medical Affairs Officer. With over 20 years of experience, Dr. Khan brings extensive expertise in medical affairs, commercial operations, and R&D. He has overseen 40+ development programs and led seven successful product launches in rare neurology and immunology indications.
Most recently at argenx, Dr. Khan headed the Neuromuscular Therapeutic Area, Medical Affairs, where he led four launches of VYVGART® products. His previous roles include leadership positions at Akouos Inc. and Sarepta Therapeutics, where he was instrumental in launching three Duchenne muscular dystrophy therapies and preparing the company's Medical Affairs organization for gene therapy programs.
RemeGen (REGMY) announced that its 48-week open-label extension data from the China Phase III clinical study of telitacicept for generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 AANEM Annual Meeting on October 29, 2025.
The previously presented 24-week data showed exceptional results with 98.1% of patients achieving ≥3 points improvement in MG-ADL score and 87% achieving ≥5 points improvement in QMG score, demonstrating the highest MG-ADL response rate among Phase III gMG treatments. In June 2025, RemeGen out-licensed telitacicept to Vor Bio (VOR), which is now conducting global Phase III trials across multiple regions.